Back to mobile site

Goldman Sachs Reiterates Buy Rating on Insmed (INSM)

May 28, 2024 1:27 PM EDT Send to a Friend
Goldman Sachs analyst Andrea Tan reiterated a Buy rating and $74.00 price target on Insmed (NASDAQ: INSM).The analyst comments "INSM ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login